Paper34068720
OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.
Kast RE and 2 others. Cells, 2021. Cited by 7 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. Papers, record 34068720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34068720
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acrylamides | Major topic |
| Adenocarcinoma of Lung | Major topic |
| Aniline Compounds | Major topic |
| Chemotherapy, Adjuvant | Major topic |
| Drug Repositioning | Major topic |
| Glioblastoma | Major topic |
| Lung Neoplasms | Major topic |
| Animals | |
| Azithromycin | |
| Carcinoma, Non-Small-Cell Lung | |
| Cell Line, Tumor | |
| Cyproheptadine | |
| Drug Resistance, Neoplasm | |
| ErbB Receptors | |
| Humans | |
| Loratadine | |
| Mice | |
| Neoplasm Metastasis | |
| Pyrimethamine | |
| Spironolactone | |
| Indoles | |
| Pyrimidines |
Source PubMed
References115
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,646,358 | Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. | Jpn J Clin Oncol | 2015 | https://conductscience.org/library/papers/25646358 | PubMed |
| 2 | 31,688,928 | Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay. | J Natl Cancer Inst | 2020 | https://conductscience.org/library/papers/31688928 | PubMed |
| 3 | 24,682,826 | A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair. | Nucleic Acids Res | 2014 | https://conductscience.org/library/papers/24682826 | PubMed |
| 4 | 7,695,295 | Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7695295 | PubMed |
| 5 | 29,970,185 | Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo. | Cancer Commun (Lond) | 2018 | https://conductscience.org/library/papers/29970185 | PubMed |
| 6 | 32,414,008 | Spironolactone and XPB: An Old Drug with a New Molecular Target. | Biomolecules | 2020 | https://conductscience.org/library/papers/32414008 | PubMed |
| 7 | 28,369,077 | Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. | PLoS One | 2017 | https://conductscience.org/library/papers/28369077 | PubMed |
| 8 | 28,710,746 | Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer. | Target Oncol | 2017 | https://conductscience.org/library/papers/28710746 | PubMed |
| 9 | 27,333,030 | Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment. | EBioMedicine | 2016 | https://conductscience.org/library/papers/27333030 | PubMed |
| 10 | 26,404,748 | Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. | Int J Cardiol | 2015 | https://conductscience.org/library/papers/26404748 | PubMed |
| 11 | 25,886,177 | Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. | BMC Cancer | 2015 | https://conductscience.org/library/papers/25886177 | PubMed |
| 12 | 30,501,602 | Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy. | Curr Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30501602 | PubMed |
| 13 | 25,211,298 | CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. | Oncotarget | 2014 | https://conductscience.org/library/papers/25211298 | PubMed |
| 14 | 27,435,396 | Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27435396 | PubMed |
| 15 | 31,590,360 | Acetylcholine Receptor Activation as a Modulator of Glioblastoma Invasion. | Cells | 2019 | https://conductscience.org/library/papers/31590360 | PubMed |
| 16 | 30,257,958 | Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30257958 | PubMed |
| 17 | 3,621,857 | Pyrimethamine in the myeloproliferative disorders: a forgotten treatment? | Clin Lab Haematol | 1987 | https://conductscience.org/library/papers/3621857 | PubMed |
| 18 | 27,559,982 | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report. | Medicine (Baltimore) | 2016 | https://conductscience.org/library/papers/27559982 | PubMed |
| 19 | 1,985,720 | A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. | Cancer | 1991 | https://conductscience.org/library/papers/1985720 | PubMed |
| 20 | 8,118,413 | The study of histamine H1- and H2-receptors in human lung cancer. | Biochem Mol Biol Int | 1993 | https://conductscience.org/library/papers/8118413 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,918,465 | Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway. | Oncol Res | 2025 | https://conductscience.org/library/papers/40918465 | PubMed |
| 40,149,682 | UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer Treatment. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149682 | PubMed |
| 39,796,688 | Synergistic Potential of Antibiotics with Cancer Treatments. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796688 | PubMed |
| 38,524,376 | IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone. | Oncoscience | 2024 | https://conductscience.org/library/papers/38524376 | PubMed |
| 35,626,167 | MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626167 | PubMed |
| 35,456,023 | EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities. | Cells | 2022 | https://conductscience.org/library/papers/35456023 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34068720
GET https://conductscience.org/api/papers/v1/34068720/references?page=2